This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

TIDES USA: Oligonucleotide & Peptide Therapeutics
May 11-14, 2026
Hynes Convention CenterBoston, MA

Ali Nahvi, Ph.D
Chief Technology Officer at Nava Therapeutics
Speaker

Profile

Ali Nahvi is the Chief Technology Officer at Nava Therapeutics where he is responsible for steering the company’s technology and innovation initiatives including chemistry, LNP discovery, targeted delivery, process development and manufacturing.

Prior to joining Nava, Ali was the Head of Platform at Flagship Pioneering’s Mirai Bio, where he helped to start the company from inception, implement the company’s scientific strategy and led it through to its next stage of growth. Previously, Ali served as Head of New Therapeutic Modalities at Spark Therapeutics and was responsible for driving research-related activities to expand the applicability of AAV and non-viral gene therapy platforms.

Ali holds a Ph.D. from Yale University and was a Life Sciences Research Foundation postdoctoral fellow at Johns Hopkins School of Medicine characterizing the mechanisms of RNA mediated gene regulation.

Agenda Sessions

  • In Vivo Generation of Functional CAR T Cells via Targeted Non-Viral Lipid Nanoparticles Enables Potent Immune Cell Depletion in Non-Human Primates

    3:00pm